Skip to main
We’re doing some system maintenance
  1. Home
  2. Stocks
  3. Emmaus Life Sciences Incorporation - Warrants (29/06/2022)
EMMAW

Buy EMMAW Stock

EMMAW
See EMMAW stock price and Buy/Sell Emmaus Life Sciences Incorporation - Warrants (29/06/2022) with any amount of money. Discuss news and analyst's price prediction with the investor community. Enter your cell phone number to get started.
EMMAW

Emmaus Life Sciences Incorporation - Warrants (29/06/2022) (EMMAW)

We couldn’t load this chart.

Some stock charts might currently not be supported. To try again, please refresh this page.

About Emmaus Life Sciences Incorporation - Warrants (29/06/2022) (EMMAW)

Emmaus Life Sciences, Inc. operates as a biopharmaceutical company. It engages in the discovery, development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories. The company was founded on March 20, 1987 and is headquartered in Torrance, CA.
Market Cap
1 Year High
Volume
1 Year Low
Price to Earnings Ratio
Open
Dividend Rate
High
Dividend Yield
Low

Community

People who own or watch EMMAW stock

EMMAW stock rating

What analysts recommend for EMMAW stock, on a scale from 1 (buy) to 5 (sell).
Buy
Sell

EMMAW price target

What analysts think EMMAW will be worth
Low $0
High $0
Current $0
Target $0

Buy EMMAW Stock

EMMAW
See EMMAW stock price and Buy/Sell Emmaus Life Sciences Incorporation - Warrants (29/06/2022) with any amount of money. Discuss news and analyst's price prediction with the investor community. Enter your cell phone number to get started.

Community

People who own or watch EMMAW stock
  • lllllllllll avatar
  • sillysassy avatar
Check the background of this firm on FINRA’s BrokerCheck.

© Copyright 2022 Public Holdings, Inc. All Rights Reserved.

Securities are offered to self-directed customers by Open to the Public Investing, Inc. (“Open to the Public Investing”), a registered broker-dealer and member of FINRA & SIPC. Additional information about your broker can be found by clicking here. Open to Public Investing is a wholly-owned subsidiary of Public Holdings Inc. (“Public Holdings”). This is not an offer, solicitation of an offer or advice to buy or sell securities, or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered. Securities products offered by Open to the Public Investing are not FDIC insured.

Cryptocurrency trading is provided by Apex Crypto LLC (“Apex Crypto”). Apex Crypto is not a registered broker-dealer or FINRA member and is not affiliated with Public Holdings or any of its subsidiaries. Cryptocurrencies are not securities and your cryptocurrency holdings are not FDIC or SIPC insured. Crypto trading involves a substantial risk of loss as there is significant volatility in the price of cryptocurrencies.

Commission-free trading of stocks and ETFs refers to $0 commissions for Open to the Public Investing self-directed individual cash brokerage accounts that trade the U.S. listed securities electronically. Keep in mind, that other fees such as regulatory fees, Premium subscription fees, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Open to the Public Investing’s Fee Schedule to learn more.

All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns.